VACCINE USAGE: MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

VACCINE DOSAGE: for intramuscular injection only (0.5 mL).

  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration.
  • In children initiating vaccination at 2 months of age, MENVEO is to be administered as a four-dose series at 2, 4, 6, and 12 months of age.
  • In children initiating vaccination at 7 months through 23 months of age, MENVEO is to be administered as a two-dose series with the second dose administered in the second year of life and at least three months after the first dose.
  • In individuals 2 years through 55 years of age Menveo is to be administered as a single dose.

VACCINE INGEDIENTS: formaldehyde, amino acids, yeast extract, Franz complete medium, CY medium.

ADVERSE VACCINE REACTIONS: irritability, sleepiness, persistent crying, change in eating habits, vomiting, diarrhea, rash, fever, appendicitis, pneumonia, staphylococcal infection, inguinal hernia, abdominal pain, labor pneumonia, viral hepatitis, hearing impaired, vertigo, hypersensitivity, vaccination site cellulitis, tonic convulsions.